Dear Reader,
Research has shown the incredible potential of psychedelic medicines to help improve mental health and investment capital is pouring into the industry.
The numbers are shocking. Nearly 1 billion people worldwide struggle with mental illness. Of these, 284 million suffer from an anxiety disorder.
300 million people suffer from depression and yet… 50-66% of patients on antidepressant drugs never make a full recovery.
Rather than relying on expensive pharmaceuticals to solve the problem, nature may already have an answer: plant-based treatments.
That’s where Ei.Ventures comes in.
As the first Psychedelic Medicine company in the world to qualify for a Reg A+ Tier 2 offering, Ei.Ventures is your ticket inside this $35 billion industry.
Their flagship product ‘Psilly’ is a Psilocybin-based formulation with natural properties that have the potential to help millions of people who struggle with mental illness, from anxiety and depression, to PTSD or alcohol and nicotine addiction, and more.
Currently, Psilly is in its pre-clinical phase, but there are big plans ahead…
Ei.Ventures recently announced a merger exploration with Mycotopia. This $360M transaction includes the formation of PSLY.COM and plans to list on NASDAQ.
Be a part of healing the world while capitalizing on a growing market.
Learn more & invest in Ei.Ventures before the opportunity closes March 22.
|